周洋，理学博士，硕士研究生导师。主要研究方向为激酶相关药物设计中计算方法的开发和应用，药物相关的自由能计算，靶标蛋白构象变化和药物分子结合/解离过程的分子机制，以及人工智能在药物研发领域的应用。

电子邮箱：zhouyang@jnu.edu.cn

2021-至今 暨南大学药学院，副研究员
2016-2020瑞典皇家理工学院，计算化学与生物学，博士
2012-2016中国科学院大学，药物化学，硕士
2007-2011天津大学，化学工程与工艺，学士，法学双学位

代表性著作
Zhou, Y.; Zou, R.; Kuang, G.; L?ngstr?m, B.; Halldin, C.; ?gren, H.; Tu, Y. Enhanced Sampling Simulations of Ligand Unbinding Kinetics Controlled by Protein Conformational Changes. J. Chem. Inf. Model.2019, 59 (9), 3910–3918.
Zou, R.; Zhou, Y.; Wang, Y.; Kuang, G.; ?gren, H.; Wu, J.; Tu, Y. Free Energy Profile and Kinetics of Coupled Folding and Binding of the Intrinsically Disordered Protein P53 with MDM2. J. Chem. Inf. Model.2020, 60 (3), 1551–1558.
Zhou, Y.; Hussain, M.; Kuang, G.; Zhang, J.; Tu, Y. Mechanistic Insights into Peptide and Ligand Binding of the ATAD2-Bromodomain via Atomistic Simulations Disclosing a Role of Induced Fit and Conformational Selection.Phys. Chem. Chem. Phys. 2018, 20 (36), 23222–23232. (PCCP Hot articles)
Ti, H.; Zhou, Y.*; Liang, X.; Li, R.; Ding, K.; Zhao, X. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). J. Med. Chem.2019, 62 (13), 5944–5978. (*co-first author)
Zhou, Y.; Nie, T.; Zhang, Y.; Song, M.; Li, K.; Ding, M.; Ding, K. K.; Wu, D.; Xu, Y. The Discovery of Novel and Selective Fatty Acid Binding Protein 4 Inhibitors by Virtual Screening and Biological Evaluation. Bioorganic Med. Chem.2016, 24 (18), 4310–4317.
Li, J.; Zhou, Y.; Tang, Y.; Li, W.; Tu, Y. Dissecting the Structural Plasticity and Dynamics of Cytochrome P450 2B4 by Molecular Dynamics Simulations. J. Chem. Inf. Model.2020, 60 (10), 5026–5035.
Zhou, Y.; Kuang, G.; Li, J.; Halldin, C.; Nordberg, A.; L?ngstr?m, B.; Tu, Y.; ?gren, H. In Silico Studies of ASEM Analogues Targeting a7-nAChR and Experimental Verification. RSC Adv. 2021, 11 (7), 3942–3951.
Zhou, H.; Zhou, Y.*; Xu, J.; Liu, L.; Ma, J.; Zhang, W.; Li, K.; Zhang, H.; Li, K. Tannic Acid-A Universal Immobilization and Fixation Agent for Nanocarbon Materials: A Novel Strategy for Aqueous Fabrication of Functional Nanocarbon Coating onto Silicon-Based Substances. ACS Sustain. Chem. Eng. 2019, 7 (22), 18534–18541. (*co-first author)
Zhao, X.; Li, R.; Zhou, Y.*; Xiao, M.; Ma, C.; Yang, Z.; Zeng, S.; Du, Q.; Yang, C.; Jiang, H.; et al. Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. J. Med. Chem.2018, 61 (12), 5187–5198. (*co-first author)
Hussain, M.; Zhou, Y.*; Song, Y.; Hameed, H. M. A.; Jiang, H.; Tu, Y.; Zhang, J. ATAD2 in Cancer: A Pharmacologically Challenging but Tractable Target. Expert Opinion on Therapeutic Targets.2018, pp 85–96. (*co-first author)
Kuang, G.; Zhou, Y.; Zou, R.; Halldin, C.; Nordberg, A.; L?ngstr?m, B.; ?gren, H.; Tu, Y. Characterization of the Binding Mode of the PET Tracer [18F]ASEM to a Chimera Structure of the Α7 Nicotinic Acetylcholine Receptor. RSC Adv. 2017, 7 (32), 19787–19793.
Kuang, G.; Murugan, N. A.; Zhou, Y.; Nordberg, A.; ?gren, H. Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. ACS Chem. Neurosci.2020, 11 (6), 900–908.
Zeng, S.; Dou, W.; Li, M.; Zhou, Y.; Guo, J.; Zhao, N.; Huang, H.; Zhou, Q.; Hu, W.; Ma, Y.; Zhao, X.; Xie, H. Discovery of an Orally Active and Long‐Acting DPP‐IV Inhibitor through Property‐Based Optimization with an in Silico Biotransformation Prediction Tool. ChemMedChem 2020, 15 (16), 1608–1617.
Makafe, G. G.; Hussain, M.; Surineni, G.; Tan, Y.; Wong, N.-K.; Julius, M.; Liu, L.; Gift, C.; Jiang, H.; Tang, Y.; Liu J.; Tan S.; Yu Z.; Liu Z.; Lu Z.; Fang C.; Zhou Y.; Zhang J.; Zhu Q.; Liu J.; Zhang T.; Quinoline Derivatives Kill Mycobacterium Tuberculosis by Activating Glutamate Kinase. Cell Chem. Biol. 2019, 26 (8), 1187-1194.e5.
Wang, Z.; Bian, H.; Bartual, S. G.; Du, W.; Luo, J.; Zhao, H.; Zhang, S.; Mo, C.; Zhou, Y.; Xu, Y.; et al. Structure-Based Design of Tetrahydroisoquinoline-7-Carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. J. Med. Chem.2016, 59 (12), 5911–5916.
Liu, T.; Wang, B.; Guo, J.; Zhou, Y.; Julius, M.; Njire, M.; Cao, Y.; Wu, T.; Liu, Z.; Wang, C.; et al. Role of FolP1 and FolP2 Genes in the Action of Sulfamethoxazole and Trimethoprim against Mycobacteria. J. Microbiol. Biotechnol. 2015, 25 (9), 1559–1567.
Zhao, X.; Zhang, Z. W.; Cui, W.; Chen, S.; Zhou, Y.; Dong, J.; Jie, Y.; Wan, J.; Xu, Y.; Hu, W. Identification of Camphor Derivatives as Novel M2 Ion Channel Inhibitors of Influenza A Virus. Med. Chem. Comm.2015, 6 (4), 727–731.
Xu, S.; Mao, L.; Ding, P.; Zhuang, X.; Zhou, Y.; Yu, L.; Liu, Y.; Nie, T.; Xu, T.; Xu, Y.; et al. 1-Benzyl-4-Phenyl-1H-1,2,3-Triazoles Improve the Transcriptional Functions of Estrogen-Related Receptor γ and Promote the Browning of White Adipose. Bioorganic Med. Chem.2015, 23 (13), 3751–3760.
Li, Y.; Cheng, H.; Zhang, Z.; Zhuang, X.; Luo, J.; Long, H.; Zhou, Y.; Xu, Y.; Taghipouran, R.; Li, D.; et al. N-(3-Ethynyl-2,4-Difluorophenyl) Sulfonamide Derivatives as Selective Raf Inhibitors. ACS Med. Chem. Lett.2015, 6 (5), 543–547.
Wang, W.; Kong, D.; Cheng, H.; Tan, L.; Zhang, Z.; Zhuang, X.; Long, H.; Zhou, Y.; Xu, Y.; Yang, X.; et al. New Benzimidazole-2-Urea Derivates as Tubulin Inhibitors. Bioorganic Med. Chem. Lett.2014, 24 (17), 4250–4253.